Dexcom Invests in Nutromics $14M Series B; Vertex and MaxCyte Partnership for CRISPR/Cas9-based Gene-editing Program
Two cardiometabolic-related news items have been observed: Nutromics announced it raised $14M in a Series B financing round for its wearable diagnostic platform led by Dexcom Ventures, VU Venture Partners, and Artesian Investments; and MaxCyte announced it signed a strategic platform license with Vertex Pharmaceuticals. Below, FENIX provides highlights and insights for the respective new items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.